The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

EJM van Bommel, MHA Muskiet, MJB van Baar, L Tonneijck, MM Smits, AL Emanuel, A Bozovic, AHJ Danser, Frank Geurts, Ewout Hoorn, DJ Touw, EL Larsen, HE Poulsen, MHH Kramer, M Nieuwdorp, JA Joles, DH van Raalte

Research output: Contribution to journalArticleAcademicpeer-review

127 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)202-212
Number of pages11
JournalKidney International
Issue number1
Publication statusPublished - 2020

Cite this